Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.770 -0.080 (-4.32%)
Streaming Delayed Price Updated: 3:02 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma Inc

< Previous 1 2 3 4 5 6 Next >
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive SPC-15 Data, Plans to File Pre-IND Application
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Exposures Product Safety
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Strategic Engagement to Step up IP and Patent Expansion Efforts
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
From Silo Pharma, Inc.
Via GlobeNewswire
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug... 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Significant Development Advancement of SPC-15
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers
Via Investor Brand Network
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
Via ACCESSWIRE
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
This month, Silo Pharma (NASDAQ: SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia an 
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent
Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted... 
Via Benzinga
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
New patent expands Company’s intellectual property and technology rights portfolio 
From Silo Pharma, Inc.
Via GlobeNewswire
Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares gained 110.8% to $1.56 in pre-market trading after the company signed a Letter of Intention with UAE-Based e-script medicine management... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.